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target lesion failure [6.2% vs 5.3% HR 1.12 (0.80 - 1.58) I2¼0%], target
lesion revascularization [4.9% vs 3.4% HR 1.40 (0.93 - 2.10) I2¼15%],
target vessel failure [8.2% vs 6.1% HR 1.24 (0.75 - 2.04) I2¼0%], target
vessel myocardial infarction [1.1% vs 1.8% HR 0.73(0.19 - 2.90)
I2¼62%], and stent thrombosis [0.4% vs 0.6% HR 0.85 (0.27 - 2.62)
I2¼0%]. There was no difference in the 2-year outcomes: Cardiac
death [2.9% vs 2.0% HR 1.43 (0.77 - 2.66) I2¼0%], target lesion failure
[7.8% vs 6.4% HR 1.22 (0.85 - 1.74) I2¼0%], and target vessel revas-
cularization [5.4% vs 3.9% HR 1.39(0.89 - 2.19) I2¼0%].
CONCLUSION The COMBO DTS showed no difference in 1- and 2-year
clinical outcomes compared to standard DES. There is a need for
further studies to identify the subgroups that may benefit from this
stent over standard DES.
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BACKGROUND The COBRA-Polyzene-F (PzF) (CeloNova Biosciences,
SanFransisco, Texas) is a novel coronary stent with PzF nano-coating.
Preclinical studies have shown that PzF has a low surface thrombo-
genicity and is known to have anti-inflammatory, bacterial resistant,
and pro-healing properties.
METHODS Between April 2017 and March 2018, out of a total of 7317
patients from the ACC-NCDR registry for patients who underwent
percutaneous coronary intervention (PCI) at 5 large hospitals, 137
received COBRA-PzF stents. Patients were grouped based on coronary
artery disease (CAD) presentation into 2 groups: acute coronary syn-
drome (ACS) (n¼47) and non-acute coronary syndrome (non-ACS)
(n¼90). Both groups were compared for various in-hospital clinical
outcomes post PCI with COBRA-PzF stents.
RESULTS Of 137 patients who received a COBRA-PzF stent, 4.26% of
patients in the ACS group had myocardial infarction as compared to
2.22% in the non-ACS group (p¼0.60) (Table 1). Similarly, cardiogenic
shock (8.51% vs 2.22%, p¼0.18) and post-procedural bleeding (6.38%
vs 1.11%, p¼0.11) were non-significantly higher in the ACS group as
compared to non-ACS group. Patients in the ACS group had non-
significantly higher in-hospital mortality (4.26%), pericardial tampo-
nade (2.13%), and dialysis requirement (4.26%), while no such events
occurred in the non-ACS group.
CONCLUSION PCI with COBRA-PzF stent showed no difference in in-
hospital outcomes between the groups. The COBRA-PzF stent can be
used safely with both ACS and non-ACS patients. Further clinical trials
should be conducted to investigate safety and efficacy of the COBRA-
PzF stent in patients with variable CAD presentation.
Table 1Cobra-PzFAcute Coronary
Syndrome (n[47)Non- Acute Coronary
Syndrome (n[90) p-valueDeath (n,%) 2 (4.26%) 0 0.11Myocardial Infarction (n,%) 2 (4.26%) 2 (2.22%) 0.6Cardiogenic shock (n,%) 4 (8.51%) 2 (2.22%) 0.18Tamponade (n,%) 1 (2.13%) 0 0.34Dialysis requirement (n,%) 2 (4.26%) 0 0.11Post-procedure bleeding (n,%) 3 (6.38%) 1 (1.11%) 0.11EMERGING DEVICES & INNOVATIVE THERAPIES
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BACKGROUND The determination of the ischemic status of a coro-
nary artery by wireless physiologic assessment derived from angiog-
raphy has been validated and approved in the US. However, the use of
plain angiography quantitative variables does not add much to the
physiology data since it has low correlation with fractional flow
reserve (FFR) and predicts clinical outcomes poorly. Recently, a gray
scale intravascular ultrasound (IVUS) derived physiology method
(IVUSFR) was developed and showed a good correlation with invasive
FFR by combining the geometric advantages of IVUS with physiology.
The aim of this study is to assess the coefficient of correlation (R) of
invasive FFR compared to IVUSFR and quantitative flow ratio (QFR).
METHODS Stable coronary artery disease (CAD) patients with interme-
diate lesions (i.e. 40–80% of diameter stenosis) were assessed by angi-
ography and IVUS. QFR was derived from the angiography images, and
IVUSFR was derived from quantitative IVUS data using computational
fluid dynamics. Coefficient of correlation (R) was used in this report.
RESULTS Twenty-four patients with 34 lesions were included in the
analysis. The IVUSFR, invasive FFR, Vessel QFR fixed flow (vQFRf),
and Vessel QFR contrast flow (vQFRc) values varied from 0.52 to 1.00,
0.71 to 0.99, 0.55 to 1.00, and 0.34 to 1.00, respectively. The coeffi-
cient of correlation (R) of FFR vs. IVUSFR was 0.79; FFR vs. vQFRf was
0.72; FFR vs. vQFRc was 0.65 (Figure).
CONCLUSION Compared to invasive FFR, IVUSFR and vQFRf showed a
similar coefficient of correlation and were better than vQFR contrast flow.
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BACKGROUND Right ventricular (RV) mechanical circulatory support
remains an important adjunctive therapy for RV failure refractory to
medical therapy. Impella RP (Abiomed, Danvers, MA) is approved for
providing temporary RV support for patients with acute right heart
failure or decompensation following acute myocardial infarction or
after major cardiac surgery. Robust data on the most commonly re-
ported complications and failure modes for the Impella RP is lacking.
We analyzed the post-marketing surveillance data from the Food and
Drug Administration Manufacturer and User Facility Device Experi-
ence (MAUDE) database to assess these endpoints.
METHODS The MAUDE database was queried from July 1, 2008,
through July 31, 2018, for Impella devices by searching for the
following event types: “injury”, “malfunction”, “death”, and “other”.
After excluding left ventricular Impella devices and incomplete re-
ports, 35 Impella RP device reports were included in the final analysis.
RESULTS In cases of reported complications, Impella RP was placed
most commonly for RV failure developing in postcardiotomy patients
(20%) followed by myocardial infarction with cardiogenic shock (14.2%)
and post left ventricular assist device placement (11.4%). The most
commonly reported complications were bleeding (42.9%) and vascular
complications (22.8%). The modes of failure included damage or frac-
ture of the device elements (34.2%); thrombus, or clot in the system
(17.1%); and device detachment (8.6%). Table 1 and Table 2 provide a
complete list of complications and modes of failure respectively.
CONCLUSIONS Findings from the MAUDE database highlight the
failure modes of the Impella RP device that should be addressed in
order to improve the device performance and obtain improved clinical
outcomes when utilized for RV failure.
